Tongkat Ali: The Testosterone Booster With Some Actual Data

What Tongkat Ali Actually Is

Tongkat Ali is the root of Eurycoma longifolia, a slender understory tree that grows across Malaysia, Indonesia, Thailand, and Vietnam. The name translates roughly to "Ali's walking stick," which tells you what it has been used for in traditional Malay medicine for a few hundred years. It also goes by longjack, pasak bumi, and tung saw depending on which country the marketing copy was written in.

The root is bitter, woody, and slow-growing. Commercial harvesting typically targets trees four years old or older, and the parts of the plant matter: the root is what the human trials use, the stem and leaves are cheaper and largely irrelevant, and a related species sold as "tongkat ali hitam" or black tongkat ali is a different plant with a much worse contamination record.

The preparation matters as much as the plant. Nearly all of the credible human research uses a standardized hot-water or aqueous root extract, usually at a concentration around 100:1, meaning 100 grams of raw root produce roughly 1 gram of extract. Two branded extracts dominate the literature: Physta, made by Biotropics Malaysia, and LJ100, developed out of a University of Malaysia and MIT collaboration. When you read a study, the extract identity is not a detail. Raw root powder at 200 mg is a completely different product from a 100:1 water extract at 200 mg, and the marketing on most bottles works hard to blur that distinction.

What makes the root interesting chemically is a family of compounds called quassinoids, and the most studied of those is eurycomanone. Quality water extracts are standardized to a stated eurycomanone percentage, commonly somewhere between 0.8 and 2.2 percent. That number is the closest thing this supplement has to a potency label, and most products do not print it.

Eurycomanone and the Mechanism Question

The proposed mechanism is more specific than the usual "supports healthy testosterone levels" hand-wave, which is part of why the compound gets taken seriously.

In cell and animal work, eurycomanone appears to increase testosterone production in Leydig cells primarily by inhibiting aromatase, the enzyme that converts testosterone into estradiol. Low 2013 in the Journal of Ethnopharmacology found eurycomanone increased testosterone dose-dependently at 0.1, 1.0, and 10.0 micromolar concentrations, and molecular docking put eurycomanone in the aromatase binding site with orientation and binding energy comparable to formestane, an actual pharmaceutical aromatase inhibitor. At higher concentrations, phosphodiesterase inhibition may contribute as well. Notably, the same work found no evidence that eurycomanone inhibits the upstream steroidogenic enzymes like CYP17.

If that mechanism holds in humans, it predicts something quite specific: testosterone should rise a little because less of it is being converted downstream, not because the testes suddenly manufacture dramatically more. It is a plumbing adjustment rather than a new pump. That prediction lines up reasonably well with what the human trials actually found, which is a modest single-digit-to-low-double-digit percentage rise in total testosterone over weeks, not the step change you would expect from an actual hormonal intervention.

The Human Trials, Ranked by Quality

Here is the full picture in one table, ordered by how much weight the design earns. Notice how the quality of the finding tracks inversely with how healthy and well-trained the population was.

Two patterns fall out of that table immediately. First, the effect sizes are largest in the least-controlled studies. Tambi 2012 produced the most quotable number in the entire literature, and it had no placebo group. Second, the populations that produced positive findings were older, stressed, hypogonadal, or deconditioned. The one trial that recruited actual trained lifters found nothing.

The Flagship Trial, Read Carefully

Chinnappan 2021, published in Food & Nutrition Research, is the trial to know. It is randomized, double-blind, placebo-controlled, run across two hospital sites, with 35 subjects per arm and 100 percent reported compliance. That is a real design, and it is the reason Tongkat Ali is a defensible topic rather than an embarrassing one.

The enrollment criteria matter more than most summaries admit. Subjects were men aged 50 to 70 with a total testosterone below 300 ng/dL, which is the common clinical threshold for hypogonadism. These were not healthy young lifters. They were men who would already be having a conversation with a urologist.

A few things deserve emphasis. The 100 mg arm only reached significance against placebo at week 12, while the 200 mg arm separated by week 4 and kept climbing. That is a clean dose-response signal, and it is why 200 mg is the number worth using rather than 100.

The symptom outcomes are arguably stronger than the hormone outcomes. Aging Male Symptoms and Fatigue Severity Scale scores dropped significantly against placebo from week 2 onward, which is fast for a 25 ng/dL testosterone move that had not even happened yet at that point. Either the symptom questionnaires are picking up something other than testosterone, or they are picking up the same cortisol reduction that shows up in Talbott 2013.

And a 12 percent rise from 200 to 225 ng/dL is a real effect that leaves a man exactly where he started clinically. For context, testosterone replacement therapy typically moves a hypogonadal man into the 500 to 900 ng/dL range. Comparing a supplement to a pharmaceutical is unfair, but it is the comparison people implicitly make when they buy the supplement to fix a low reading.

The Free Testosterone Problem

This is the part of the Tongkat Ali story that almost never survives the trip from journal to product page.

Roughly 98 percent of circulating testosterone is bound to sex hormone binding globulin or albumin and is biologically unavailable. The fraction that actually does anything is free testosterone, plus the loosely albumin-bound portion. When a supplement moves total testosterone but leaves free testosterone unchanged, the practical significance of that move is genuinely unclear.

In Chinnappan 2021, free testosterone showed no significant between-group difference versus placebo at any timepoint, in either the 100 mg or 200 mg arm. There were significant within-group increases compared to each group's own baseline, but within-group comparisons in a trial that has a placebo arm are the weaker analysis, and the placebo group's free testosterone also drifted upward across the same 12 weeks. SHBG did not change either, which rules out the mechanism that makes boron interesting.

The 2022 meta-analysis by Leisegang and colleagues in Medicina pooled five RCTs and reported a standardized mean difference of 1.352 for total testosterone, with a 95 percent confidence interval running from 0.565 to 2.138. A confidence interval that wide, spanning "small effect" to "enormous effect," is the statistical signature of high heterogeneity across a small number of studies with different populations, doses, extracts, and durations. The authors themselves concluded that more research is needed before clinical use, and specified hypogonadal men as the most promising target.

The Trial Nobody Quotes

In 2024, researchers published a randomized, placebo-controlled trial in Applied Sciences that asked the question this site cares about most: what does Tongkat Ali do for people who already lift?

Thirty-three exercise-trained males and females, mean age 33.1 years, with a mean of 13.9 years of training experience, took either 400 mg of Tongkat Ali or a rice flour placebo daily for four weeks. That is double the dose used in the flagship hypogonadal trial, in a healthy trained population, under placebo control.

The measured outcomes were body mass, lean body mass, fat mass, body fat percentage, total body water, Profile of Mood States, handgrip strength, Pittsburgh Sleep Quality Index, vigilant attention, and in a subset, salivary cortisol and free testosterone.

Nothing moved. No between-group differences on any outcome. Lean body mass changed by -0.5 kg in the treatment group and -0.4 kg in placebo. Fat mass changed by -0.5 kg treatment and +0.3 kg placebo, well within noise for a 33-person sample over four weeks.

Two honest caveats. Four weeks is short, and the flagship trial's between-group total testosterone separation appeared at week 4 and kept growing through week 12, so a longer trial in trained lifters might read differently. And 33 subjects split into two groups is underpowered to detect a small effect. But this is the only placebo-controlled trial that recruited the exact population buying most of the product, and its answer was no.

That fits a pattern that shows up across the entire supplement category, and it is worth naming plainly: interventions that correct a deficit look powerful, and the same intervention added on top of a normal state looks like nothing. Raising a 200 ng/dL man to 225 is a different biological event than adding a capsule to a 33-year-old with 13 years under the bar and a normal panel. Nearly every disappointing supplement experience traces back to buying the first study and living in the second situation. The same logic runs through multivitamins, vitamin D, and zinc.

Cortisol Is Probably the Better Story

Strip out the testosterone marketing and look at what replicates. Cortisol reduction shows up in Talbott 2013 (salivary cortisol down 16 percent over four weeks in moderately stressed adults) and again in Chinnappan 2021 (significant cortisol decrease at 200 mg, p < 0.01). Mood and fatigue outcomes improved in both.

Talbott 2013 is worth reading on its own terms. It recruited 63 moderately stressed adults, both men and women, gave them 200 mg of a standardized hot-water extract for four weeks, and measured salivary hormones plus a validated mood inventory. Tension fell 11 percent, anger 12 percent, confusion 15 percent. Salivary testosterone rose 37 percent, though salivary testosterone is a noisier measure than serum and that number should be treated as directional.

If the compound's real action is a modest downward pressure on cortisol, several things make more sense at once. The symptom scores improving before the testosterone move. The strongest effects landing in stressed and aging populations. The null result in well-rested trained lifters whose cortisol was presumably fine to begin with. Testosterone and cortisol also share a substrate pool and an inverse relationship under chronic stress, so a cortisol drop can drag testosterone up a little without the compound doing anything directly androgenic.

That framing puts Tongkat Ali much closer to ashwagandha than to anything anabolic, and it also means the intervention it is competing against is sleep. Eight hours beats 200 mg of anything on this list, costs nothing, and has never had a contamination recall.

Who Paid for the Research

The conflict of interest situation here is not hidden, but it also does not appear in a single product description.

Chinnappan 2021 states plainly in its disclosure that two of the authors, including the corresponding author, are employees of Biotropics Malaysia Berhad, and that Biotropics Malaysia Berhad funded the study. Biotropics manufactures Physta, the extract being tested. Several of the other trials in the literature likewise test a single branded extract with sponsor involvement.

This does not make the results fake. Industry-funded trials get published, get peer reviewed, and can be well designed, and Chinnappan 2021 is better designed than plenty of independently funded nutrition research. But the pattern across medicine is consistent: industry-sponsored studies report favorable results more often than independent ones, through publication decisions, endpoint selection, and dose choices rather than through fraud.

The practical implication is narrow and useful. The independent trial in this literature, the 2024 Applied Sciences study in trained lifters, is the one that found nothing. Weight the evidence accordingly. Our guide to fitness influencer red flags covers why "there are studies" is a claim that needs the funding line read out loud.

Dosing, Form, and Timeline

Dose. 200 mg per day of a standardized water extract of the root is the number with the most controlled human evidence behind it. The 100 mg arm in the head-to-head trial was slower and weaker. The 400 mg arms in the two trained and senior populations did not outperform 200 mg on anything, and one of them found nothing at all. There is no dose-response evidence supporting the 600 mg to 1,000 mg doses that have become common on product labels.

Form. A hot-water or aqueous extract of the root, standardized to a stated eurycomanone content, at roughly a 100:1 ratio. Raw root powder is not the same thing and cannot be dosed against the trial literature. Ethanol extracts have a different compound profile and much less human data.

Timing. Irrelevant. This is a slow shift in steroidogenesis measured over weeks, not an acute effect. Take it whenever you will remember to take it, with food to reduce the chance of stomach upset. The one exception is that some people report it disrupts their sleep if taken late, in which case move it to morning.

Timeline. Four weeks is the minimum honest trial length, twelve is better. In Chinnappan 2021 the 200 mg group separated from placebo on total testosterone at week 4 and the gap continued widening at weeks 8 and 12. Judging this compound after two weeks tells you nothing.

Cycling. There is no evidence for or against cycling because no trial has run long enough to establish tolerance or its absence. The longest controlled trial is six months. Anyone giving you a confident cycling protocol is extrapolating past the data.

The Product Quality Disaster

Everything above concerns a 12 percent effect under ideal conditions. Here is the part that determines whether you get any effect at all.

A commercial product analysis found that more than half of the Tongkat Ali products tested contained no detectable eurycomanone, the primary quassinoid used in every clinical trial. Twenty-seven percent were adulterated with entirely different plant species. Products in this category have also been reported adulterated with sildenafil, the active drug in Viagra, which explains a certain flavor of enthusiastic review and is a genuine cardiovascular hazard for anyone on nitrates.

Heavy metals are the second problem, and they are structural rather than fraudulent. Eurycoma longifolia root is a bioaccumulator that pulls metals out of the soil it grows in. One analysis found 36 percent of tested Tongkat Ali preparations carried 0.52 to 5.30 ppm of mercury, against a Malaysian traditional-medicine limit of 0.5 ppm. The worst offenders in that literature were "tongkat ali hitam" black tongkat preparations, which are a different plant and should be avoided outright.

None of this is unique to Tongkat Ali. It is the predictable output of a supplement market where, under the US Dietary Supplement Health and Education Act, products do not require pre-market approval for safety or efficacy and identity testing is the manufacturer's own responsibility. It just happens to be unusually bad here because the raw material is expensive, slow-growing, geographically concentrated, and easy to counterfeit with cheaper roots.

Safety, Side Effects, and Who Should Skip It

The clinical trial safety record for a quality extract at trial doses is good. Chinnappan 2021 ran complete blood counts, lipid panels, and liver and renal function tests across 12 weeks at 100 and 200 mg and reported no clinically relevant changes. A separate two-month study of 600 mg per day of LJ100 in healthy men aged 38 to 58 found no adverse changes in blood profiles or liver and kidney function markers. Reported side effects across trials are mild and uncommon: some gastrointestinal upset, occasional headache, occasional insomnia, generally in under 5 percent of participants.

Three real caveats sit underneath that clean record.

Idiosyncratic liver injury has been reported. A 2024 case report in Cureus described a 47-year-old man who developed jaundice, scleral icterus, and elevated liver enzymes after starting Tongkat Ali, was hospitalized, and improved after discontinuing it. The pattern was mild hepatocellular injury. One case report across a very widely used supplement is a low absolute risk, and it is also the kind of signal that means "stop immediately and get labs if you develop fatigue, dark urine, or yellowing," rather than "this is safe for everyone."

Long-term human safety is undocumented. The longest controlled trial ran six months. Nobody has studied what daily use for five years does, and the LiverTox monograph notes the general absence of adverse-effect data in the systematic review literature.

The contamination risk exceeds the pharmacological risk. A mercury-contaminated capsule is a bigger threat to you than eurycomanone is. This is why the certificate of analysis section above is the most practically important part of this article.

Who should skip it entirely:

• Anyone with existing liver or kidney disease. The margin is not worth a 12 percent hormone move.
• Men with prostate cancer or an elevated PSA. Any intervention that raises androgens warrants a physician conversation first.
• Anyone taking nitrates or with significant cardiovascular disease, given the documented sildenafil adulteration risk in this category.
• Pregnant or breastfeeding women. No safety data exists.
• Tested athletes. Tongkat Ali is not on the WADA prohibited list, but supplements in the testosterone category carry a well-documented adulteration risk, and a positive test is your problem regardless of the label. Use NSF Certified for Sport products only, or skip it.
• Anyone under 25 with no symptoms and no blood panel. You are the population where every trial found nothing.

Tongkat Ali vs the Rest of the T-Booster Aisle

The category is mostly noise, and this table exists to give the noise a scale. Grades reflect the strength and independence of the human evidence, not the enthusiasm of the marketing.

That last row is not a throwaway. Restricting sleep to five hours a night for one week drops daytime testosterone by roughly 10 to 15 percent in healthy young men, which is the same order of magnitude as the entire effect the flagship Tongkat Ali trial produced over 12 weeks. Losing meaningful body fat if you are carrying excess moves it further. Spending money on the supplement while sleeping six hours is paying to fix a leak upstream of the hole you drilled.

What to Realistically Expect

Here is the honest expectation-setting, split by who you actually are.

If you are a man over 45 with a measured total testosterone under 300 ng/dL: expect a modest rise in total testosterone over 4 to 12 weeks, a meaningful improvement in fatigue and general symptom scores that may show up faster than the hormone change, and no change in free testosterone that you could distinguish from placebo. Expect it to remain a supplement rather than a treatment. If your reading is genuinely low and symptomatic, the correct move is a conversation with a physician about causes, because low testosterone in a 50-year-old can be a symptom of sleep apnea, obesity, thyroid dysfunction, medication effects, or a pituitary problem, and none of those are fixed by a root extract.

If you are a stressed adult of either sex with normal hormones: the cortisol and mood data is the reason to try it, and Talbott 2013 included women. Expect a modest effect on tension, fatigue, and perceived stress over four weeks. Expect ashwagandha to do a similar job with more independent evidence.

If you are a trained lifter under 40 with a normal panel: expect nothing, because the only placebo-controlled trial in that population found nothing on any of ten measured outcomes. Your money is better spent on creatine monohydrate, which has hundreds of trials, costs a few dollars a month, and produces a measurable effect in exactly your population.

What nobody should expect: visible body composition change attributable to the supplement, a strength jump, a libido transformation that outlasts the first month of expectancy, or a testosterone reading that moves into a different clinical category.

Common Mistakes

Buying it without a baseline blood panel. Every positive trial enrolled men with documented low testosterone. Without a number, you cannot know whether you are in the population the research applies to, and you will end up judging the supplement by feel, which is the least reliable instrument you own.

Buying raw root powder and dosing it like extract. 200 mg of a 100:1 water extract represents roughly 20 grams of raw root. 200 mg of root powder is 200 mg of root powder. These are not interchangeable, and plenty of cheap products blur the line deliberately.

Ignoring the certificate of analysis. Given that over half of tested products had no detectable eurycomanone and 36 percent of preparations in one analysis exceeded the mercury limit, the COA is doing more work than the dose is.

Judging it in two weeks. The flagship trial's between-group separation appeared at week 4 and grew through week 12. A two-week trial measures your expectations.

Megadosing past 200 mg. The dose-response evidence supports 200 mg over 100 mg. It does not support anything above that, and the two trials using 400 mg are the ones that found the least.

Stacking it into a blend and calling it a test. If you start Tongkat Ali, a new pre-workout, and a sleep stack in the same week, you have learned nothing about any of them. Change one variable.

Using it instead of fixing sleep, bodyweight, or alcohol intake. Each of those moves testosterone more than this does, and the alcohol data in particular is uncomfortable reading for most lifters.

Frequently Asked Questions

Does Tongkat Ali actually raise testosterone?

In men who start low, yes, modestly. The best-controlled trial is a 12-week randomized, double-blind, placebo-controlled study in 105 men aged 50 to 70 with total testosterone under 300 ng/dL. The 200 mg group went from 200.5 to 225.0 ng/dL while placebo drifted from 183.0 to 177.9 ng/dL, a between-group difference of roughly 12 percent that reached statistical significance from week 4 onward. Free testosterone showed no significant between-group difference in the same trial, and SHBG did not change. In healthy trained lifters the picture is different: a 2024 randomized placebo-controlled trial in 33 exercise-trained men and women taking 400 mg for four weeks found no change in salivary free testosterone, cortisol, body composition, handgrip strength, mood, or sleep.

How much Tongkat Ali should I take and for how long?

The dose with the most controlled human data behind it is 200 mg per day of a standardized water extract of the root, roughly a 100:1 concentration. Trials at 100 mg produced smaller and slower effects than 200 mg in a direct head-to-head, and trials at 400 mg in trained and senior populations did not outperform 200 mg. Timeline matters more than dose: significant changes appeared at week 4 and grew through week 12, so anything under four weeks is not a fair test. Take it daily with food at any time of day, since the mechanism is a slow shift in steroidogenesis rather than an acute stimulant effect. If it disrupts your sleep, move it to the morning.

Is Tongkat Ali safe?

At 200 to 600 mg per day of a quality extract, the clinical trial record is clean. A two-month study of 600 mg daily in healthy men found no adverse changes in liver or kidney function tests, and the 12-week placebo-controlled trial reported no clinically relevant safety findings on blood count, lipids, or liver and renal panels. Two caveats apply. A 2024 case report in Cureus documented acute hepatocellular liver injury in a 47-year-old man that resolved after discontinuation, so idiosyncratic reactions happen even if they are rare. And the product-quality problem is the bigger practical safety issue: analyses have found mercury above the Malaysian traditional-medicine limit in 36 percent of tested preparations, and adulteration with sildenafil has been reported in this product category.

How do I know if a Tongkat Ali product is real?

Assume it is not unless the label proves otherwise. A commercial product analysis found that more than half of Tongkat Ali products tested had no detectable eurycomanone, the main quassinoid studied in the human trials, and 27 percent were adulterated with entirely different plant species. Buy only a named, standardized water extract of the root that states its eurycomanone percentage, comes with a current batch-specific third-party certificate of analysis covering identity and heavy metals, and ideally carries NSF or USP certification. The root is a heavy-metal bioaccumulator, so the heavy-metal panel is not optional. Avoid anything labeled black tongkat or tongkat ali hitam, which is a different plant with the worst contamination record in the literature.

Is Tongkat Ali better than ashwagandha for testosterone?

They target overlapping problems and the honest answer is that both produce modest effects in stressed or hypogonadal men and unimpressive effects in healthy trained lifters. Tongkat Ali has more direct total testosterone data in men who start below 300 ng/dL. Ashwagandha has a deeper evidence base for cortisol reduction, anxiety, and sleep quality, with testosterone as a secondary and less consistent finding. If the underlying complaint is chronic stress and poor sleep, ashwagandha is the more defensible first pick. If it is a documented low testosterone reading in an older man, Tongkat Ali has the more relevant trials. Neither substitutes for a blood panel and a physician.

Will Tongkat Ali build muscle or improve my lifts?

There is no good evidence that it will in a trained lifter who already has normal testosterone. The 2024 randomized trial in exercise-trained males and females with an average of nearly 14 years of training experience measured lean body mass, fat mass, body fat percentage, total body water, handgrip strength, mood, sleep, and salivary hormones after four weeks at 400 mg, and found no between-group differences on any of them. The strength and force findings that do exist come from older, deconditioned, or hypogonadal populations, where raising testosterone from a deficient level toward a normal one is a fundamentally different intervention than adding a supplement on top of an already normal level.

The Bottom Line

Tongkat Ali is the most defensible product in an aisle full of nonsense, and that is a low bar it clears by a smaller margin than the marketing suggests.

The evidence is real. A 12-week randomized, double-blind, placebo-controlled multicentre trial in 105 hypogonadal men found a statistically significant roughly 12 percent rise in total testosterone at 200 mg, with clear dose-response against the 100 mg arm and significant improvements in fatigue and aging-symptom scores. A 2022 meta-analysis of five RCTs found a significant pooled increase in total testosterone. Cortisol reduction replicates across two independent trials.

The limits are equally real. Free testosterone, the fraction that actually does anything, showed no between-group difference against placebo. The 12 percent rise left those men below the clinical threshold they were enrolled under. The flagship trial was funded by the company that makes the extract, and two of its authors work there. And the only placebo-controlled trial that recruited healthy trained lifters found nothing across ten outcomes.

Layered on top of all of that is a supply chain where over half of tested products had no detectable active compound, a quarter were the wrong plant, and a third of preparations in one analysis exceeded a national mercury limit. The effect size under ideal conditions is modest. The probability that the capsule in your hand delivers those ideal conditions is a coin flip at best.

So the practical answer splits cleanly. If you are an older man with a documented low reading, 200 mg of a certified, standardized water extract for at least twelve weeks is a reasonable thing to try alongside, and not instead of, a proper medical workup. If you are a trained lifter with a normal panel, the research says your money buys you nothing here, and it says so in the only study that actually asked.

References

1. Chinnappan, S.M., George, A., Pandey, P., Narke, G., & Choudhary, Y.K. (2021). Effect of Eurycoma longifolia standardised aqueous root extract-Physta on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study. Food & Nutrition Research, 65, 5647.
2. Leisegang, K., Finelli, R., Sikka, S.C., & Panner Selvam, M.K. (2022). Eurycoma longifolia (Jack) improves serum total testosterone in men: a systematic review and meta-analysis of clinical trials. Medicina, 58(8), 1047.
3. Talbott, S.M., Talbott, J.A., George, A., & Pugh, M. (2013). Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects. Journal of the International Society of Sports Nutrition, 10, 28.
4. Tambi, M.I.B.M., Imran, M.K., & Henkel, R.R. (2012). Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? Andrologia, 44(Suppl 1), 226-230.
5. Henkel, R.R., Wang, R., Bassett, S.H., Chen, T., Liu, N., Zhu, Y., & Tambi, M.I. (2014). Tongkat Ali as a potential herbal supplement for physically active male and female seniors: a pilot study. Phytotherapy Research, 28(4), 544-550.
6. Leitao, A.E., Vieira, M.C.S., Pelegrini, A., da Silva, E.L., & Guimaraes, A.C.A. (2021). A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM). Maturitas, 145, 78-85.
7. The effect of Tongkat Ali supplementation on body composition in exercise-trained males and females (2024). Applied Sciences, 14(11).
8. Low, B.S., Choi, S.B., Abdul Wahab, H., Das, P.K., & Chan, K.L. (2013). Eurycomanone, the major quassinoid in Eurycoma longifolia root extract, increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis. Journal of Ethnopharmacology, 149(1), 201-207.
9. Kaliounji, A., & Shadid, A. (2024). A rare case of Tongkat Ali-induced liver injury: a case report. Cureus, 16(3).
10. National Institute of Diabetes and Digestive and Kidney Diseases. Tongkat Ali. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD.
11. Ang, H.H., Lee, E.L., & Matsumoto, K. (2006). Contamination of mercury in tongkat Ali hitam herbal preparations. Food and Chemical Toxicology, 44(8), 1245-1250.
12. Rehman, S.U., Choe, K., & Yoo, H.H. (2016). Review on a traditional herbal medicine, Eurycoma longifolia Jack (Tongkat Ali): its traditional uses, chemistry, evidence-based pharmacology and toxicology. Molecules, 21(3), 331.
13. Choudhary, Y.K., Bommu, P., Ming, Y.K., & Zulkawi, N.B. (2012). Acute, sub-acute, and subchronic 90-days toxicity of Eurycoma longifolia aqueous extract in Sprague Dawley rats. International Journal of Pharmacy and Pharmaceutical Sciences, 4(3), 232-238.
14. Li, C.H., Liao, J.W., Liao, P.L., Huang, W.K., Tse, L.S., Lin, C.H., Kang, J.J., & Cheng, Y.W. (2013). Evaluation of acute 13-week subchronic toxicity and genotoxicity of the powdered root of Tongkat Ali (Eurycoma longifolia Jack). Evidence-Based Complementary and Alternative Medicine, 2013, 102987.
15. Leproult, R., & Van Cauter, E. (2011). Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA, 305(21), 2173-2174.